Study of a Bone Assessment Technique, Bone Mineral Analyser, Concerning the Prediction of Improvement in Bone Status After an Infusion of Zoledronic Acid in Osteoporotic Women (TEOBASO)

University Hospital, Rouen

Status

Unknown

Conditions

Osteoporosis

Treatments

Diagnostic Test: Bone mineral analyser

Study type

Interventional

Funder types

Other

Identifiers

2017/183/HP

Details and patient eligibility

About

Enrollment

72 estimated patients

Sex

Female

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Women < 85 years old
Postmenopausal women (amenorrhea for more than 12 months), a confirmation diagnosis should be obtained (amenorrhea for at least 12 months before the inclusion visit).
Post-menopausal osteoporosis with one or more severe fractures (upper end of the humerus, femur, or tibia; 3 adjacent ribs; lower end of the femur; thoracic or lumbar spine; pelvis), or T score <-3 which justifies setting up a bisphosphonate treatment
Affiliated to social security

Exclusion criteria

Contraindication to zoledronic acid (allergy to the product, creatinine clearance <35 ml / min, hypocalcemia, open and unhealed lesions of the soft tissues of the mouth)
Hormone replacement therapy taken in the last 12 months
Osteoprotective treatment (bisphosphonates, teriparatide, raloxifene, strontium ralenate or denosumab) taken in the last 12 months
Secondary osteoporosis: hyperthyroidism, hyperparathyroidism, long-term corticosteroid therapy, hypercorticism, hypogonadism, treatment with anti aromatases / LHRH analogues, neoplastic pathology (solid or hemopathy)
History of bilateral wrist or femur fracture
Person deprived of liberty by an administrative or judicial decision or person placed under the protection of justice / guardianship or curatorship
Patient participating in another trial / having participated in another trial within 6 months